Profile of patients treated with intravitreal antiangiogenics in a Brazilian public service with high level of complexity
2022

Profile of Patients Treated with Intravitreal Antiangiogenics in Brazil

Sample size: 429 publication Evidence: moderate

Author Information

Author(s): Isadora Andrade Rabelo, Marina Crespo Soares, Andrea Mara Simões Torigoe

Primary Institution: Hospital das Clínicas, Universidade Estadual de Campinas, Campinas, SP, Brazil

Hypothesis

This study aimed to describe the clinical and epidemiological profile of patients undergoing intravitreal antiangiogenic therapy in a tertiary referral hospital in Brazil.

Conclusion

The study provides insights into the clinical and epidemiological profile of patients receiving antiangiogenic therapy, highlighting the need for better understanding and optimization of treatment in Brazil.

Supporting Evidence

  • Bevacizumab was the most commonly used intravitreal injectable medicine (79.38%).
  • Macular edema was the most prevalent pathology indicative of treatment (60.12%).
  • Treatment adherence was associated with the patient’s pathology.

Takeaway

Doctors looked at the health records of 429 patients who got eye injections to help with vision problems. They found that many patients didn't follow their treatment plans.

Methodology

This cross-sectional, retrospective, and observational study analyzed medical records of patients who received intravitreal injections of antiangiogenic agents for retinal diseases.

Limitations

The study had a short follow-up period, which may limit the conclusions drawn.

Participant Demographics

The majority of patients were male (51.28%), white (80.89%), aged between 50 and 80 years (mean age 60.92), and had primary education (56.88%).

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.5935/0004-2749.2022-0119

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication